Keywords: astrazeneca, outperformer, say, msdw, analysts, morgan, stanley
AstraZeneca an outperformer, say MSDW analysts
Article | 26 July 1999
Analysts at Morgan Stanley Dean Witter have lowered by 9% theirfull-year 1999 estimates for AstraZeneca, following the disposal of specialty chemicals and ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
